• Citer

Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study

par Awada, Ahmad ;Garcia, Agustin A;Chan, Stephen;Jerusalem, Guy;Coleman, Robert;Huizing, Manon T;Mehdi, Aminder;O'Reilly, Sue M;Hamm, John T;Barrett-Lee, Peter;Cocquyt, Véronique;Sideras, Kostandinos;Young, David E;Zhao, Carol;Chia, Yen Lin;Hoch, Ute;Hannah, Alison L;Perez, Edith A
Référence Lancet oncology, 14, 12, page (1216-1225)
Publication Publié, 2013-11

Article révisé par les pairs

• Accès en ligne
• Détails
• Contenu
• Statistiques

Titre:	Two schedules of etirinotecan pegol (NKTR-102) in patients with previously treated metastatic breast cancer: A randomised phase 2 study
Auteur:	Awada, Ahmad; Garcia, Agustin A; Chan, Stephen; Jerusalem, Guy; Coleman, Robert; Huizing, Manon T; Mehdi, Aminder; O'Reilly, Sue M; Hamm, John T; Barrett-Lee, Peter; Cocquyt, Véronique; Sideras, Kostandinos; Young, David E; Zhao, Carol; Chia, Yen Lin; Hoch, Ute; Hannah, Alison L; Perez, Edith A
Informations sur la publication:	Lancet oncology, 14, 12, page (1216-1225)
Statut de publication:	Publié, 2013-11
Sujet CREF:	Cancérologie
MeSH keywords:	Adult
	Aged
	Aged, 80 and over
	Breast Neoplasms -- drug therapy -- mortality -- secondary
	Camptothecin -- administration & dosage -- adverse effects -- analogs & derivatives -- pharmacokinetics
	Drug Administration Schedule
	Europe
	Female
	Heterocyclic Compounds with 4 or More Rings -- administration & dosage -- adverse effects -- pharmacokinetics
	Humans
	Intention to Treat Analysis
	Kaplan-Meier Estimate
	Middle Aged
	Polyethylene Glycols -- administration & dosage -- adverse effects -- pharmacokinetics
	Time Factors
	Topoisomerase I Inhibitors -- administration & dosage -- adverse effects -- pharmacokinetics
	Treatment Outcome
	United States
Note générale:	SCOPUS: ar.j
Langue:	Anglais
Identificateurs:	urn:issn:1470-2045
	info:doi/10.1016/S1470-2045(13)70429-7
	info:pii/S1470204513704297
	info:scp/84886725282
	info:pmid/24095299